Protection against infection from the omicron variant of the coronavirus was low. For children ages 6 months to 2 years, efficacy was 43.7 percent, and in children ages 2 to 6, it was only 37.5 percent. Moderna said the majority of the infections were mild. There were no cases of severe illness, hospitalization or death.Centers for Disease Control and Prevention
Moderna's vaccine should reduce the risk of hospitalization or serious illness in kids, even if it doesn't stop infection, said Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto. Moderna said it plans to submit the data to the Food and Drug Administration and other regulators in the coming weeks.
energisch_ 😂 your children, your choice!
And STILL US FDA hasn’t scheduled Novavax approval review meeting for ANY age group for US citizens that paid $1.8 Billion to fund this. We just sit and wait while the rest of the world receives safe, protein based vaccine. For us? mRNA (Pfizer). Can you report on WHY that is?